Ignite Creation Date:
2025-12-24 @ 6:28 PM
Ignite Modification Date:
2026-02-26 @ 2:16 AM
Study NCT ID:
NCT02658968
Status:
COMPLETED
Last Update Posted:
2024-01-16
First Post:
2015-12-22
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
Sponsor:
Nordic Nanovector
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Radioimmunotherapy | View |
| None | Lu-177 | View |
| None | Phase I study | View |
| None | Betalutin | View |
| None | ARC | View |
| None | Antibody Radionuclide Conjugate | View |
| None | HH1 | View |
| None | Rituximab | View |
| None | 177Lu-DOTA-HH1 | View |
| None | Lilotomab | View |
| None | Lutetium (177Lu)-lilotomab satetraxetan | View |
| None | Additional relevant MeSH terms: | View |
| None | Lymphoma | View |
| None | Lymphoma, Non-Hodgkin | View |
| None | Immune System Diseases | View |
| None | Immunoproliferative Disorders | View |
| None | Diffuse Large B-Cell Lymphoma | View |
| None | Lymphatic Diseases | View |
| None | Lymphoproliferative Disorders | View |
| None | Neoplasms | View |
| None | Neoplasms by Histologic Type | View |
| None | DLBCL | View |
| None | Refractory DLBCL | View |
| None | Relapsed DLBCL | View |